Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis

W Zhu; F C Tenover; J Limor; D Lonsway; D Prince; W M Dunne Jr; J B Patel

doi:10.1007/s10096-007-0261-0

Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis

Eur J Clin Microbiol Infect Dis. 2007 Mar;26(3):161-5. doi: 10.1007/s10096-007-0261-0.

Authors

W Zhu¹, F C Tenover, J Limor, D Lonsway, D Prince, W M Dunne Jr, J B Patel

Affiliation

¹ Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, MS-G08, Atlanta, GA 30333, USA.

PMID: 17393201
DOI: 10.1007/s10096-007-0261-0

Abstract

A pyrosequencing assay was used for the rapid characterization of linezolid-resistant isolates of Staphylococcus aureus and Staphylococcus epidermidis. The assay identified base substitutions in copies of the 23S rRNA gene and determined the percentage of alleles with the mutation. Modifications of the assay were necessary to identify all mutations in the 23S rRNA genes of S. epidermidis that were associated with linezolid resistance. A C2534T mutation was identified in S. epidermidis that was not previously reported in a linezolid-resistant isolate.

MeSH terms

Acetamides / pharmacology*
Anti-Infective Agents / pharmacology*
Base Sequence
DNA Primers
Drug Resistance, Bacterial
Humans
Linezolid
Microbial Sensitivity Tests
Molecular Sequence Data
Oxazolidinones / pharmacology*
Point Mutation*
Polymorphism, Single Nucleotide / genetics*
RNA, Ribosomal, 23S / genetics*
Staphylococcus aureus / drug effects
Staphylococcus aureus / genetics*
Staphylococcus epidermidis / drug effects
Staphylococcus epidermidis / genetics*

Substances

Acetamides
Anti-Infective Agents
DNA Primers
Oxazolidinones
RNA, Ribosomal, 23S
Linezolid